Skip to content
Arvinas logo
Search
Close
Arvinas logo
Search
Close

Publication Year: 2019

A New Therapeutic Strategy for Tauopathies: Discovery of Highly Potent Brain Penetrant Tau PROTAC® Degrader Molecules

ARV-110: an oral androgen receptor PROTAC® degrader for prostate cancer

Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
Menu
  • Careers
  • Privacy Policy
  • Terms of Use
Linkedin-in Twitter

© 2023 Arvinas. All rights reserved.

Arvinas logo
Search
Close
  • Our Science
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Partnerships
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Research & Development
    • Pipeline
    • Androgen Receptor
    • Estrogen Receptor
    • Neuroscience
  • Careers & Culture
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Patients
    • Patients with Breast Cancer
    • Patients with Prostate Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Menu
  • Contact Us
Linkedin-in Twitter
Skip to content